Related Experiment Video
Updated: Aug 14, 2026

Trabecular Bone Microarchitecture Evaluation in an Osteoporosis Mouse Model
Published on: September 8, 2023
Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in
Hiroko Yamazaki1, Takahisa Sasaki
1Department of Oral Histology, School of Dentistry, Showa University, Shinagawa-ku, Tokyo, Japan.
Abstract:
Osteoprotegerin (OPG)-deficient mice exhibit severe bone loss including the destruction of growth plate cartilage. Using OPG-deficient mice, we attempted to clarify the differentiation and ultrastructure of osteoclasts located on the destroyed growth plate cartilage and trabecular bone matrix in long bones. In (-/-) homozygous OPG knockout mice, adjacent to the growth plate cartilage, the formation of bone trabeculae without a calcified cartilaginous core resulted in an irregular chondrocyte distribution in the growth plate cartilage. At the metaphyseal ossification center, TRAP-positive osteoclasts showed unusual localization on both type-II collagen-positive cartilage and type-I collagen-positive bone matrix. Osteoclasts located on cartilage matrix lacked a typical ruffled border structure, but formed resorption lacunae. During growth plate cartilage destruction, osteoclasts formed ruffled border structures on bone matrix deposited on the remaining cartilage surfaces. These findings suggest that, in OPG (-/-) mice, osteoclast structure differs, depending on the matrix of either cartilage or bone. Then, we examined the effects of OPG administration on the internal trabecular bone structure and osteoclast differentiation in OPG (-/-) mice. OPG administration to OPG (-/-) mice significantly inhibited trabecular bone loss and maintained the internal trabecular bone structure, but did not reduce the osteoclast number on bone trabeculae. For most osteoclasts, OPG administration caused disappearance or reduction of the ruffled border, but induced neither necrotic nor apoptotic damages. These results suggest that OPG administration is an effective means of maintaining the internal structure and volume of trabecular bone in metabolic bone diseases by inhibition of osteoclastic bone resorption.
Insights
Osteoprotegerin (OPG) deficiency causes severe bone loss and growth plate destruction. OPG administration effectively preserves bone structure by inhibiting osteoclast resorption, offering a potential treatment for metabolic bone diseases.
Area of Science:
- Skeletal Biology
- Bone Metabolism
- Developmental Biology
Background:
- Osteoprotegerin (OPG) deficiency leads to severe bone loss and growth plate cartilage destruction.
- Osteoclasts play a critical role in bone resorption and cartilage degradation.
Purpose of the Study:
- To investigate osteoclast differentiation and ultrastructure on destroyed growth plate cartilage and trabecular bone in OPG-deficient mice.
- To evaluate the therapeutic effect of OPG administration on bone structure and osteoclast activity in OPG-deficient mice.
Main Methods:
- Utilized OPG-deficient (OPG-/-) mice to study bone loss and osteoclast behavior.
- Examined osteoclast localization, morphology, and resorption activity on cartilage and bone matrices.
- Assessed the impact of OPG administration on trabecular bone structure and osteoclast characteristics.
Main Results:
- OPG deficiency resulted in irregular chondrocyte distribution and bone trabeculae formation without calcified cores.
- TRAP-positive osteoclasts exhibited unusual localization on both cartilage and bone matrices, with altered ruffled border structures.
- OPG administration preserved trabecular bone structure and volume by inhibiting osteoclast resorption, without reducing osteoclast numbers or inducing cell death.
Conclusions:
- Osteoclast structure and function are matrix-dependent in OPG deficiency.
- OPG administration is a promising therapeutic strategy for maintaining bone integrity in metabolic bone diseases by modulating osteoclast resorption.
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Remodeling
